Serum CXCL12 concentration in patients with severe traumatic brain injury are associated with mortality.
CXC chemokine ligand-12 (CXCL12) is released during brain injury. The objective of this study was to investigate relationship between serum CXCL12 concentration, mortality and trauma severity in patients with traumatic brain injury (TBI). We determined serum CXCL12 concentration of 132 controls and 132 patients with severe TBI. Trauma severity was assessed using Glasgow Coma Scale (GCS) score. The end-point of the study was 30-day mortality. Serum CXCL12 concentration were significantly higher in the patients than in the controls (13.3±6.8 vs. 1.5±0.5 ng/ml, P<0.001). There was a negative correlation between CXCL12 concentration and GCS scores (r=-0.588, P<0.001). The optimal cutoff value of CXCL12 as a mortality indicator was estimated to be 15.4 ng/ml, which yielded a sensitivity of 71.0% and a specificity of 72.2%, with the area under curve at 0.808 [95% confidence (CI), 0.730-0.871]. Serum CXCL12 concentration>19.5 ng/ml were associated independently with 30-day mortality (odds ratio, 6.951; 95% CI, 2.027-18.477; P<0.001) and 30-day overall survival (hazard ratio, 4.398; 95% CI, 2.088-15.286; P<0.001). Increased serum CXCL12 concentration is associated highly with trauma severity and mortality following TBI.